News for Agenus Inc. (AGEN)

Agenus (AGEN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Agenus Inc. (”œAgenus” or the ”œCompany”) (Nasdaq: AGEN), an immuno-oncology company focused on innovation, today announced the results of its national [

**media[568943]**

Cash Balance: Ended 2024 with $40.4 million, down from $76.1 million at the end of 2023.Cash Used in Operations: $158 million for the year ended December 31, 2

Mar 11, 2025 / 12:30PM GMTOperator Good morning, and welcome to Agenus Inc.'s fourth-quarter and year-end 2024 earnings conference call. (Operator Instructions)

Agenus Inc. (NASDAQ:AGEN) Q4 2024 Earnings Conference Call March 11, 2025 8:30 AM ETCompany ParticipantsZack Armen - Head of Investor Relations, Corporate...

Agenus Inc. (”œAgenus” or the ”œCompany”) (Nasdaq: AGEN), an immuno-oncology company advancing innovative cancer therapies, today reported financial and

Agenus (AGEN) delivered earnings and revenue surprises of 13.56% and 20.21%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

LEXINGTON, Mass. — Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company advancing innovative cancer therapies, today reported financi…

Agenus (AGEN) reports Q4 GAAP EPS of -$2.04, beating estimates by $0.50. Revenue down 68% YoY. Operational cash burn reduced to $28.7M.

**media[552077]**

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today highlights key scientific contributions in 2024-2025 that are shaping the future of c

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today presented data at the American Association for Cancer Research (AACR) IO Annual Meeting in Los A

**media[548588]**

Proffered Papers, Session 2, Session Date and Time of release dated February 12, 2025, should read: Monday, February 24th, 1:39-1:45 p.m. PST (instead of Tuesd

Here is how Agenus (AGEN) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that BOT/BAL will be featured in two presentations at the upcoming American Associatio

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Agenus (AGEN) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Here is how Agenus (AGEN) and Concentra Group (CON) have performed compared to their sector so far this year.